Memantine Macleods

Memantine Hydrochloride, the active ingredient in Memantine Macleods, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults. By modulating glutamatergic activity, it helps reduce neuronal excitotoxicity associated with disease progression.

GNH USA supplies Memantine Macleods as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Memantine acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease.

Alzheimer’s disease (moderate to severe): improves cognition and functional abilities in patients with advanced disease. Alzheimer’s disease (mild to moderate) as adjunct therapy: may enhance benefits when combined with cholinesterase inhibitors. Behavioral disturbances in Alzheimer’s disease: can help reduce agitation and aggression in some patients.

Memantine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: transient mental clouding. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin disorder. - Hepatic dysfunction: abnormal liver enzymes. - Cardiac arrhythmia: irregular heart rhythm. - Psychosis: new or worsening hallucinations or delusions.

Memantine should be used with caution in specific clinical situations.

Renal impairment: dose adjustment may be required. History of seizures: monitor for increased seizure activity. Cardiovascular disease: use cautiously due to potential blood pressure effects. Concurrent NMDA antagonists: avoid combined use to prevent additive CNS depression. Pregnancy and lactation: safety unknown; avoid unless clearly needed. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Memantine may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase CNS effects. - Ketamine: combined use can lead to excessive sedation or respiratory depression. - Strong CYP450 inhibitors (e.g., ketoconazole): may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors: may diminish therapeutic benefit. - Diuretics: can potentiate hypotensive effects. - Alcohol: may enhance dizziness and sedation.